Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting

Rhea-AI Summary

Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.

Positive

• Presentation of Phase 2a clinical trial data for atacicept demonstrates promising results.
• Opportunity to share findings with a global audience at a prominent nephrology conference.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today the upcoming presentation of clinical data for the Company’s lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be presented as an ePoster at the American Society of Nephrology Kidney Week 2021 Annual Meeting, being held virtually November 4-7, 2021.

Vera Therapeutics’ ePoster session information is as follows:

Title: Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients
Session Title: PO1203-3. Glomerular Diseases: Treatment and Outcomes
Abstract Number: PO1638

Full abstracts will be available on the meeting platform on Friday, October 15, 2021 on a rolling basis. All ePosters will be available on Thursday, November 4, 2021 at 10:00 AM PT and will remain available until Friday, January 7, 2022.

About Vera
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN). For more information, please visit www.veratx.com.

Contacts
Investor Contact:
IR@veratx.com

Media Contact:
Greig Communications, Inc.
Kathy Vincent
(310) 403-8951
kathy@greigcommunications.com

FAQ

What clinical trial data will Vera present at the American Society of Nephrology Kidney Week 2021?

Vera Therapeutics will present data from the Phase 2a JANUS clinical trial for atacicept, focusing on its effects in patients with IgA nephropathy.

When will the ePoster session for Vera's atacicept data take place?

The ePoster session will take place during the American Society of Nephrology Kidney Week from November 4-7, 2021.

What is the significance of atacicept in treating IgA nephropathy?

Atacicept aims to block factors that stimulate B cells and plasma cells, potentially leading to improved treatments for IgA nephropathy.

How does atacicept work in the treatment of IgA nephropathy?

Atacicept is a fusion protein that self-administers as a subcutaneous injection, targeting autoantibody production by inhibiting BLyS and APRIL.